157 related articles for article (PubMed ID: 33098154)
1. Safety of Off-Label Use of Ferumoxtyol as a Contrast Agent for MRI: A Systematic Review and Meta-Analysis of Adverse Events.
Ahmad F; Treanor L; McGrath TA; Walker D; McInnes MDF; Schieda N
J Magn Reson Imaging; 2021 Mar; 53(3):840-858. PubMed ID: 33098154
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.
Nguyen KL; Yoshida T; Kathuria-Prakash N; Zaki IH; Varallyay CG; Semple SI; Saouaf R; Rigsby CK; Stoumpos S; Whitehead KK; Griffin LM; Saloner D; Hope MD; Prince MR; Fogel MA; Schiebler ML; Roditi GH; Radjenovic A; Newby DE; Neuwelt EA; Bashir MR; Hu P; Finn JP
Radiology; 2019 Dec; 293(3):554-564. PubMed ID: 31638489
[TBL] [Abstract][Full Text] [Related]
3. What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent.
Varallyay CG; Toth GB; Fu R; Netto JP; Firkins J; Ambady P; Neuwelt EA
AJNR Am J Neuroradiol; 2017 Jul; 38(7):1297-1302. PubMed ID: 28495944
[TBL] [Abstract][Full Text] [Related]
4. MRI with ferumoxytol: A single center experience of safety across the age spectrum.
Nguyen KL; Yoshida T; Han F; Ayad I; Reemtsen BL; Salusky IB; Satou GM; Hu P; Finn JP
J Magn Reson Imaging; 2017 Mar; 45(3):804-812. PubMed ID: 27480885
[TBL] [Abstract][Full Text] [Related]
5. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia.
Wise-Faberowski L; Velasquez N; Chan F; Vasanawala S; McElhinney DB; Ramamoorthy C
Cardiol Young; 2018 Jul; 28(7):916-921. PubMed ID: 29848399
[TBL] [Abstract][Full Text] [Related]
6. Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis.
Schieda N; van der Pol CB; Walker D; Tsampalieros AK; Maralani PJ; Woo S; Davenport MS
Radiology; 2020 Dec; 297(3):565-572. PubMed ID: 32452732
[TBL] [Abstract][Full Text] [Related]
7. Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.
Behzadi AH; Zhao Y; Farooq Z; Prince MR
Radiology; 2018 Feb; 286(2):471-482. PubMed ID: 28846495
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults.
Ning P; Zucker EJ; Wong P; Vasanawala SS
Magn Reson Imaging; 2016 Feb; 34(2):152-8. PubMed ID: 26518061
[TBL] [Abstract][Full Text] [Related]
9. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults.
Muehe AM; Feng D; von Eyben R; Luna-Fineman S; Link MP; Muthig T; Huddleston AE; Neuwelt EA; Daldrup-Link HE
Invest Radiol; 2016 Apr; 51(4):221-227. PubMed ID: 26656202
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough Hypersensitivity Reactions to Gadolinium-based Contrast Agents and Strategies to Decrease Subsequent Reaction Rates: A Systematic Review and Meta-Analysis.
Walker DT; Davenport MS; McGrath TA; McInnes MDF; Shankar T; Schieda N
Radiology; 2020 Aug; 296(2):312-321. PubMed ID: 32427558
[TBL] [Abstract][Full Text] [Related]
11. Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.
Adams LC; Jayapal P; Ramasamy SK; Morakote W; Yeom K; Baratto L; Daldrup-Link HE
AJR Am J Roentgenol; 2023 Apr; 220(4):590-603. PubMed ID: 36197052
[TBL] [Abstract][Full Text] [Related]
12. Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study.
Dasi A; Kring DN; Selvaraj B; Morgan P; Gerity C; Morgan EE; Krishnamurthy R; Krishnamurthy R
Pediatr Radiol; 2023 Dec; 53(13):2622-2632. PubMed ID: 37837456
[TBL] [Abstract][Full Text] [Related]
13. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.
Daldrup-Link HE; Theruvath AJ; Rashidi A; Iv M; Majzner RG; Spunt SL; Goodman S; Moseley M
Pediatr Radiol; 2022 Feb; 52(2):354-366. PubMed ID: 34046709
[TBL] [Abstract][Full Text] [Related]
14. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study.
Iv M; Ng NN; Nair S; Zhang Y; Lavezo J; Cheshier SH; Holdsworth SJ; Moseley ME; Rosenberg J; Grant GA; Yeom KW
Radiology; 2020 Nov; 297(2):438-446. PubMed ID: 32930651
[TBL] [Abstract][Full Text] [Related]
15. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
Nayak AB; Luhar A; Hanudel M; Gales B; Hall TR; Finn JP; Salusky IB; Zaritsky J
Pediatr Nephrol; 2015 Mar; 30(3):515-21. PubMed ID: 25212105
[TBL] [Abstract][Full Text] [Related]
16. Safety and technique of ferumoxytol administration for MRI.
Vasanawala SS; Nguyen KL; Hope MD; Bridges MD; Hope TA; Reeder SB; Bashir MR
Magn Reson Med; 2016 May; 75(5):2107-11. PubMed ID: 26890830
[TBL] [Abstract][Full Text] [Related]
17. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography.
Stabi KL; Bendz LM
Ann Pharmacother; 2011 Dec; 45(12):1571-5. PubMed ID: 22045905
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of ferumoxytol in the treatment of iron deficiency: a systematic review and meta-analysis.
Abdulrehman J; Tang GH; Auerbach M; Santesso N; Sholzberg M
Transfusion; 2019 Dec; 59(12):3646-3656. PubMed ID: 31762068
[TBL] [Abstract][Full Text] [Related]
19. Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents.
Hojreh A; Peyrl A; Bundalo A; Szepfalusi Z
PLoS One; 2020; 15(4):e0230781. PubMed ID: 32243440
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
